metabolomics
(3)
Daojing Wang
Daojing Wang is the founder, president, and CEO of Newomics, a Berkeley biotech building chip-based mass spectrometry tools for precision medicine. A Princeton-trained chemist who spent 11 years as a principal investigator at Lawrence Berkeley National Laboratory, he co-invented the M3 emitter and multinozzle emitter array (MEA) - a silicon shower-head that makes mass spectrometers far more sensitive. He spun the technology out of the national lab in 2013 and has since shipped well over 100 systems to labs worldwide.
Jack Geremia
Jack Geremia is the CEO and co-founder of Matterworks, a Somerville, Massachusetts biotech building Large Spectral Models - foundation models that read raw mass spectrometry signals the way a large language model reads text. A Princeton-trained chemist and former Caltech quantum-control postdoc turned serial biotech founder, he has spent 25-plus years moving technologies from lab bench to market, authoring more than 100 patents and publications. After co-founding Matterworks in 2019 as advising CTO, he stepped into the CEO seat to commercialize Pyxis, the company's generative-AI engine for untargeted molecular annotation, and led the company through a 2025 Series A from Lewis & Clark Partners and OMX Ventures.
Abhishek Jha
Abhishek Jha is the Co-Founder and CEO of Elucidata, a San Francisco-based AI company making biomedical data AI-ready for drug discovery and pharmaceutical R&D. A trained physical chemist with a PhD from the University of Chicago and postdoctoral work at MIT, he spent years at Agios Pharmaceuticals contributing to four FDA-approved first-in-class therapies before co-founding Elucidata in 2015. Under his leadership, the company has raised over $22.7M in funding, grown to 170 employees, and achieved $22.2M ARR, while evolving from a data-curation platform into an AI company solving out-of-distribution (OOD) problems in biomedical research - work that earned Elucidata recognition as one of Fast Company's Most Innovative Companies in 2024.